Early results back M-Biotech's implantable glucose monitor
This article was originally published in Clinica
Executive Summary
M-Biotech says that proof-of-concept data look promising for its new implantable glucose biosensor. The device, which the firm claims is "unlike other implantable systems", targets a market worth over $1bm in the US alone, says the company.